Xerient

Company Overview

Snapshot

Founded in May 2019 by Guy Yachin, Xerient operates with 1–10 employees. The company has raised $5.03 million across 3 funding rounds from 2 investors.

Business overview

Xerient is a Health Tech & Life Sciences company focused on addressing unmet needs in cancer treatment, specifically within abdominal and gastrointestinal cancers. The company develops novel therapeutics and diagnostic technologies aimed at significantly improving patient survival. Xerient is introducing a portfolio of products designed to treat hard-to-treat cancers in the abdominal/GI area, beginning with solutions for pancreatic cancer. It operates in the Pharma & Medical Biotechnology and Drugs Discovery & Development sectors, targeting healthcare providers.

Company Intelligence Q&A

What is Xerient's primary focus in cancer treatment?

Xerient is focused on developing novel therapeutics and diagnostic technologies for abdominal and gastrointestinal cancers, with an initial emphasis on pancreatic cancer.

When was Xerient founded?

Xerient was founded in May 2019.

Who is the CEO and Co-founder of Xerient?

Guy Yachin is the Co-founder and CEO of Xerient.